Literature DB >> 8238222

A prospective trial of intraoperative fluorouracil during trabeculectomy in a black population.

P R Egbert1, A S Williams, K Singh, P Dadzie, T B Egbert.   

Abstract

In a study population of black Africans with advanced glaucoma in Ghana we conducted a prospective study of intraoperative 5-fluorouracil alone. Eyes undergoing trabeculectomy were randomly selected either to receive or not receive a single intraoperative application of 5-fluorouracil (50 mg/ml for five minutes). Fifty-five eyes had a mean follow-up of 282 days (minimum, 92 days). Twenty of 24 eyes (83%) in the 5-fluorouracil group vs 12 of 31 eyes (39%) in the control group had postoperative intraocular pressure of 20 mm Hg or less with or without medical therapy (P = .01). Eleven of 24 eyes (46%) in the 5-fluorouracil group and five of 31 eyes (16%) in the control group had intraocular pressure of 15 mm Hg or less (P = .02). Without medical therapy, 17 of 24 eyes (71%) in the 5-fluorouracil group and ten of 31 eyes (32%) in the control group had intraocular pressure of 20 mm Hg or less (P = .02). The overall complications were similar in the two groups. In this population, intraoperative 5-fluorouracil markedly improved the ability of trabeculectomy to lower intraocular pressure. We recommend that intraoperative 5-fluorouracil be considered in glaucoma surgery with poor prognosis as an alternative to postoperative subconjunctival injections when multiple injections are not feasible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8238222     DOI: 10.1016/s0002-9394(14)73204-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  19 in total

Review 1.  Glaucoma in West Africa: a neglected problem.

Authors:  Peter R Egbert
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Comparison of 90-s versus 5-min intraoperative 5-fluorouracil in trabeculectomy.

Authors:  Andrea Zarkovic; Kent Chow; Justin S Mora
Journal:  Int Ophthalmol       Date:  2009-01-10       Impact factor: 2.031

3.  Sponge delivery variables and tissue levels of 5-fluorouracil.

Authors:  M R Wilkins; N L Occleston; A Kotecha; L Waters; P T Khaw
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

Review 4.  Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans.

Authors:  Y Lachkar; M Leyland; P Bloom; C Migdal
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

5.  Long term results of glaucoma surgery among participants in an east African population survey.

Authors:  H A Quigley; R R Buhrmann; S K West; I Isseme; M Scudder; M S Oliva
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

6.  A randomised trial of the effect of intraoperative 5-FU on the outcome of trabeculectomy in east Africa.

Authors:  D Yorston; P T Khaw
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

7.  A randomised, prospective study comparing trabeculectomy with viscocanalostomy with adjunctive antimetabolite usage for the management of open angle glaucoma uncontrolled by medical therapy.

Authors:  D P S O'Brart; M Shiew; B Edmunds
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

8.  Low-dose transscleral diode laser cyclophotocoagulation (TSCPC) as a potential single treatment for primary open-angle glaucoma (POAG) in Malawi?

Authors:  Markus Schulze Schwering; Petros Kayange; Volker Klauss; Khumbo Kalua; Martin S Spitzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-21       Impact factor: 3.117

9.  Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa.

Authors:  C Mielke; V K Dawda; N Anand
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

10.  National survey of antimetabolite use in glaucoma surgery in the United Kingdom.

Authors:  D Siriwardena; B Edmunds; R P L Wormald; P T Khaw
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.